Welcome to our dedicated page for Cyclacel Pharma SEC filings (Ticker: CYCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) SEC filings page on Stock Titan is intended to organize the company’s regulatory disclosures for investors who follow this clinical-stage biopharmaceutical issuer. Cyclacel develops cancer medicines based on cell cycle, epigenetics, transcriptional regulation and mitosis biology, and its filings with the U.S. Securities and Exchange Commission provide formal detail on this strategy, its lead PLK1 inhibitor plogosertib, and its capital structure.
In Cyclacel’s periodic reports such as Form 10-K annual reports and Form 10-Q quarterly reports, investors can typically review pipeline descriptions, risk factors and financial statements. The company has publicly discussed focusing development resources on the plogosertib clinical program, the deconsolidation and liquidation of its UK subsidiary Cyclacel Limited, and the resulting impact on research and development expenses and UK tax credits. These topics are usually expanded upon in management’s discussion and analysis sections of SEC filings.
Current Reports on Form 8-K are particularly relevant for tracking material events that Cyclacel has already described in press releases, such as private placements of Series F Convertible Preferred Stock with associated warrants, declarations of quarterly cash dividends on its 6% Convertible Exchangeable Preferred Stock, reverse stock splits of its common stock, and the Exchange Agreement with FITTERS Diversified Berhad to acquire Fitters Sdn. Bhd. Filings related to Nasdaq notices on minimum bid price compliance or changes to the company’s capital structure also appear in this category.
Stock Titan’s platform is designed to surface real-time updates from EDGAR so that new Cyclacel Forms 10-K, 10-Q, 8-K and any registration statements, such as a Form S-4 for the proposed exchange transaction, can be accessed as they are filed. In addition, investors can review ownership and insider activity through Forms 3, 4 and 5, where applicable, to understand how directors and officers transact in CYCC securities. AI-powered summaries on Stock Titan help explain the key points of lengthy filings, highlighting items such as clinical program focus, going concern discussions, financing arrangements and the status of strategic transactions, without replacing the need to read the full SEC documents.
Bio Green Med Solution, Inc. entered into a Securities Purchase Agreement with foreign accredited investors to sell 1,103,338 shares of common stock at $0.72 per share, raising aggregate gross proceeds of $794,403. The closing occurred on June 10, 2026, and the company plans to use the cash for general corporate and operating purposes.
At the same time, the company signed a Registration Rights Agreement requiring it to file and maintain an effective resale registration statement so investors can later resell these shares under the Securities Act or Rule 144. The shares were issued without registration under Regulation S to non‑U.S. persons.
Bio Green Med Solution, Inc. entered into a Securities Purchase Agreement with foreign accredited investors to sell 1,103,338 shares of common stock at $0.72 per share, raising aggregate gross proceeds of $794,403. The closing occurred on June 10, 2026, and the company plans to use the cash for general corporate and operating purposes.
At the same time, the company signed a Registration Rights Agreement requiring it to file and maintain an effective resale registration statement so investors can later resell these shares under the Securities Act or Rule 144. The shares were issued without registration under Regulation S to non‑U.S. persons.
Bio Green Med Solution, Inc. entered into a Business Combination Agreement to acquire Future NRG Sdn. Bhd. in an all‑stock share exchange. Future NRG will become a wholly owned subsidiary, while its selling shareholders are expected to own more than 99% of the combined company, leaving pre‑transaction Bio Green Med holders with less than 1%.
The deal aims to build a next‑generation environmental platform by combining Bio Green Med’s fire safety equipment business with Future NRG’s medical waste‑to‑energy operations in Malaysia. Closing requires shareholder approvals, Nasdaq listing approval for new shares, effectiveness of a Form S‑4 registration statement and other customary conditions, and may be terminated if not completed by December 31, 2026.
Bio Green Med Solution, Inc. entered into a Business Combination Agreement to acquire Future NRG Sdn. Bhd. in an all‑stock share exchange. Future NRG will become a wholly owned subsidiary, while its selling shareholders are expected to own more than 99% of the combined company, leaving pre‑transaction Bio Green Med holders with less than 1%.
The deal aims to build a next‑generation environmental platform by combining Bio Green Med’s fire safety equipment business with Future NRG’s medical waste‑to‑energy operations in Malaysia. Closing requires shareholder approvals, Nasdaq listing approval for new shares, effectiveness of a Form S‑4 registration statement and other customary conditions, and may be terminated if not completed by December 31, 2026.
Bio Green Med Solution, Inc. reported its first full quarter focused on Malaysian fire-safety operations after exiting biopharma. For the three months ended March 31, 2026, revenue was $778,000, all from fire-safety products and services, with cost of sales of $635,000 and general and administrative expenses of $389,000, resulting in an operating loss of $246,000 and net loss of $197,000.
Cash and cash equivalents were $3.3 million and working capital was $4.8 million as of March 31, 2026, against an accumulated deficit of $454.6 million. Management expects existing cash to fund operations only into the fourth quarter of 2026 and explicitly states there is substantial doubt about the company’s ability to continue as a going concern without new financing or a strategic transaction.
The quarter reflects the consolidation of Fitters Sdn. Bhd., the Malaysian fire-safety subsidiary acquired in September 2025, and the absence of prior biopharma research and development, which has been fully discontinued. The company’s 6% Convertible Exchangeable Preferred Stock has been delisted from Nasdaq, although the common stock continues to trade under the ticker BGMS.
Bio Green Med Solution, Inc. reported its first full quarter focused on Malaysian fire-safety operations after exiting biopharma. For the three months ended March 31, 2026, revenue was $778,000, all from fire-safety products and services, with cost of sales of $635,000 and general and administrative expenses of $389,000, resulting in an operating loss of $246,000 and net loss of $197,000.
Cash and cash equivalents were $3.3 million and working capital was $4.8 million as of March 31, 2026, against an accumulated deficit of $454.6 million. Management expects existing cash to fund operations only into the fourth quarter of 2026 and explicitly states there is substantial doubt about the company’s ability to continue as a going concern without new financing or a strategic transaction.
The quarter reflects the consolidation of Fitters Sdn. Bhd., the Malaysian fire-safety subsidiary acquired in September 2025, and the absence of prior biopharma research and development, which has been fully discontinued. The company’s 6% Convertible Exchangeable Preferred Stock has been delisted from Nasdaq, although the common stock continues to trade under the ticker BGMS.
Bio Green Med Solution, Inc. reported first quarter 2026 results showing its transition into fire safety operations gaining traction but still producing a small loss. Product revenue from fire safety equipment reached $0.8 million for the three months ended March 31, 2026, with cost of sales of $0.6 million, reflecting an early revenue base in the new business.
General and administrative expenses fell sharply to $0.4 million from $4.2 million a year earlier, mainly as one-time change-of-control costs rolled off and management focused on tighter cost control. The company recorded a net loss of $0.2 million, similar to the prior-year loss from continuing and discontinued operations combined.
Cash and cash equivalents were $3.3 million as of March 31, 2026, and Bio Green Med estimates these resources will fund planned expenditures into the fourth quarter of 2026. During the quarter, its 6% Convertible Exchangeable Preferred Stock was delisted from Nasdaq, although the common stock remains listed, and holders of the preferred received a $0.15 per-share quarterly cash dividend paid on May 1, 2026.
Bio Green Med Solution, Inc. reported first quarter 2026 results showing its transition into fire safety operations gaining traction but still producing a small loss. Product revenue from fire safety equipment reached $0.8 million for the three months ended March 31, 2026, with cost of sales of $0.6 million, reflecting an early revenue base in the new business.
General and administrative expenses fell sharply to $0.4 million from $4.2 million a year earlier, mainly as one-time change-of-control costs rolled off and management focused on tighter cost control. The company recorded a net loss of $0.2 million, similar to the prior-year loss from continuing and discontinued operations combined.
Cash and cash equivalents were $3.3 million as of March 31, 2026, and Bio Green Med estimates these resources will fund planned expenditures into the fourth quarter of 2026. During the quarter, its 6% Convertible Exchangeable Preferred Stock was delisted from Nasdaq, although the common stock remains listed, and holders of the preferred received a $0.15 per-share quarterly cash dividend paid on May 1, 2026.
Bio Green Med Solution, Inc. reports an amended Schedule 13G/A showing that Yap Kim Choy beneficially owns 467,535 shares of common stock, representing 8.47% of the class. The filing lists sole voting and dispositive power over the 467,535 shares.
The disclosure provides a snapshot of a significant passive ownership stake in the company as reported by the holder; timing and any change versus prior holdings are not stated in the provided excerpt.
Bio Green Med Solution, Inc. reports an amended Schedule 13G/A showing that Yap Kim Choy beneficially owns 467,535 shares of common stock, representing 8.47% of the class. The filing lists sole voting and dispositive power over the 467,535 shares.
The disclosure provides a snapshot of a significant passive ownership stake in the company as reported by the holder; timing and any change versus prior holdings are not stated in the provided excerpt.
Bio Green Med Solution, Inc. filed Amendment No. 1 to its Schedule 14A to replace the incorrect virtual meeting link in the Definitive Proxy Statement. The company schedules its 2026 Annual Meeting as a virtual audio webcast at 12:30 p.m. E.D.T. on June 18, 2026.
The proxy materials state the record date was April 20, 2026, with 5,519,456 shares of Common Stock outstanding as of that date and 135,537 shares of Preferred Stock outstanding. Proposals include election of two Class I directors, ratification of SFAI Malaysia Plt. as auditors, and an advisory vote on executive compensation. The Board recommends a vote FOR each proposal and provides the corrected virtual meeting URL: www.virtualshareholdermeeting.com/BGMS2026.
Bio Green Med Solution, Inc. filed Amendment No. 1 to its Schedule 14A to replace the incorrect virtual meeting link in the Definitive Proxy Statement. The company schedules its 2026 Annual Meeting as a virtual audio webcast at 12:30 p.m. E.D.T. on June 18, 2026.
The proxy materials state the record date was April 20, 2026, with 5,519,456 shares of Common Stock outstanding as of that date and 135,537 shares of Preferred Stock outstanding. Proposals include election of two Class I directors, ratification of SFAI Malaysia Plt. as auditors, and an advisory vote on executive compensation. The Board recommends a vote FOR each proposal and provides the corrected virtual meeting URL: www.virtualshareholdermeeting.com/BGMS2026.
Bio Green Med Solution, Inc. is asking shareholders to vote at its 2026 virtual annual meeting on June 18, 2026 at 12:30 p.m. E.D.T. via www.proxyvote.com. Holders of common stock as of April 20, 2026, when 5,519,456 shares were outstanding, may vote.
Shareholders will vote on three proposals: re‑electing Class I directors Dr. Satis Waran Nair Krishnan and Inigo Angel Laurduraj for terms expiring in 2029, ratifying SFAI Malaysia Plt. as independent auditor for 2026, and approving executive compensation on an advisory basis.
The board, which has five members and fully independent audit, compensation, and governance committees, unanimously recommends voting in favor of all proposals. The filing details 2025 executive pay, including RSU grants to CEO Datuk Dr. Doris Wong and CFO Kiu Cu Seng, significant 2025 net losses, and large historical share‑price declines reflected in total shareholder return metrics.
Bio Green Med Solution, Inc. is asking shareholders to vote at its 2026 virtual annual meeting on June 18, 2026 at 12:30 p.m. E.D.T. via www.proxyvote.com. Holders of common stock as of April 20, 2026, when 5,519,456 shares were outstanding, may vote.
Shareholders will vote on three proposals: re‑electing Class I directors Dr. Satis Waran Nair Krishnan and Inigo Angel Laurduraj for terms expiring in 2029, ratifying SFAI Malaysia Plt. as independent auditor for 2026, and approving executive compensation on an advisory basis.
The board, which has five members and fully independent audit, compensation, and governance committees, unanimously recommends voting in favor of all proposals. The filing details 2025 executive pay, including RSU grants to CEO Datuk Dr. Doris Wong and CFO Kiu Cu Seng, significant 2025 net losses, and large historical share‑price declines reflected in total shareholder return metrics.
Bio Green Med Solution, Inc. announced that its Board of Directors declared a quarterly cash dividend of $0.15 per share on its 6% Convertible Exchangeable Preferred Stock. The dividend will be paid on May 1, 2026 to preferred stockholders of record at the close of business on April 23, 2026.
Bio Green Med Solution, Inc. announced that its Board of Directors declared a quarterly cash dividend of $0.15 per share on its 6% Convertible Exchangeable Preferred Stock. The dividend will be paid on May 1, 2026 to preferred stockholders of record at the close of business on April 23, 2026.
Bio Green Med Solution, Inc. completed a major strategic pivot in 2025, exiting most drug development and becoming a Malaysia-focused supplier and trader of fire safety equipment through the acquisition of Fitters Sdn. Bhd. for 699,158 new common shares, equal to 19.99% of its stock.
The company deconsolidated its former R&D subsidiary Cyclacel Limited after a creditors’ voluntary liquidation, increasing stockholders’ equity by about $4.9 million, then repurchased and later sold its Plogosertib assets for up to $470,000. It raised $3.1 million via Series C and D preferred stock and later concentrated ownership in a new investor.
BGMS now distributes certified fire extinguishers, foam systems, PYRODOR fire doors, PPE and safety apparel into Malaysian commercial, industrial and government markets, but highlights substantial doubt about its ability to continue as a going concern, high customer concentration, intense competition, regulatory dependence and the need for additional capital.
Bio Green Med Solution, Inc. completed a major strategic pivot in 2025, exiting most drug development and becoming a Malaysia-focused supplier and trader of fire safety equipment through the acquisition of Fitters Sdn. Bhd. for 699,158 new common shares, equal to 19.99% of its stock.
The company deconsolidated its former R&D subsidiary Cyclacel Limited after a creditors’ voluntary liquidation, increasing stockholders’ equity by about $4.9 million, then repurchased and later sold its Plogosertib assets for up to $470,000. It raised $3.1 million via Series C and D preferred stock and later concentrated ownership in a new investor.
BGMS now distributes certified fire extinguishers, foam systems, PYRODOR fire doors, PPE and safety apparel into Malaysian commercial, industrial and government markets, but highlights substantial doubt about its ability to continue as a going concern, high customer concentration, intense competition, regulatory dependence and the need for additional capital.
Bio Green Med Solution, Inc. reported its first fire-safety product revenue after shifting away from biopharmaceuticals. For 2025, product revenue from fire safety equipment was $0.7 million, while net loss narrowed sharply to $3.0 million from $11.2 million in 2024.
Cash and cash equivalents were $3.5 million as of December 31, 2025, and the company expects existing cash to fund operations into the third quarter of 2026. Results reflect the September 2025 acquisition of Fitters Sdn. Bhd., liquidation of the U.K. subsidiary, and sale of the Plogosertib drug asset, which together produced a $4.9 million gain on deconsolidation and $0.3 million from the asset sale.
R&D expenses fell to $0.8 million for 2025 from $6.7 million in 2024 as legacy drug programs wound down, while general and administrative costs rose to $7.7 million due to one-time change-of-control expenses. A quarterly dividend of $0.15 per share was paid on the 6% Convertible Exchangeable Preferred Stock, and a warrant exchange triggered a large deemed dividend of $11.0 million to common shareholders.
Bio Green Med Solution, Inc. reported its first fire-safety product revenue after shifting away from biopharmaceuticals. For 2025, product revenue from fire safety equipment was $0.7 million, while net loss narrowed sharply to $3.0 million from $11.2 million in 2024.
Cash and cash equivalents were $3.5 million as of December 31, 2025, and the company expects existing cash to fund operations into the third quarter of 2026. Results reflect the September 2025 acquisition of Fitters Sdn. Bhd., liquidation of the U.K. subsidiary, and sale of the Plogosertib drug asset, which together produced a $4.9 million gain on deconsolidation and $0.3 million from the asset sale.
R&D expenses fell to $0.8 million for 2025 from $6.7 million in 2024 as legacy drug programs wound down, while general and administrative costs rose to $7.7 million due to one-time change-of-control expenses. A quarterly dividend of $0.15 per share was paid on the 6% Convertible Exchangeable Preferred Stock, and a warrant exchange triggered a large deemed dividend of $11.0 million to common shareholders.